Home >  Diabetes and Endocrinology MDTV >  Diabetes & Endocrinology Shorts >  Trial Shows Tirzepatide...

Trial Shows Tirzepatide May Benefit People with Obesity, Kidney Disease and Heart Failure

By - Dr. Bhumika Maikhuri
Published On 2025-04-03 02:45 GMT   |   Update On 2025-04-03 09:53 GMT
Advertisement
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to study published in Journal of the American College of Cardiology. The overall rate of cardiovascular death or worsening heart failure, the trial’s primary endpoint, was higher in the 60% of study participants who also had
chronic kidney disease. However, tirzepatide reduced the risk of the primary endpoint to a similar degree in patients with and without kidney disease.
In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have interacting root causes and are associated with poor outcomes, indicating a significant unmet need.
Advertisement
The SUMMIT trial enrolled 731 patients with heart failure with preserved ejection fraction and a body mass index of 30 m2/kg or higher. About 60% of the study participants also had chronic kidney disease. Half were randomly assigned to receive tirzepatide and half received a placebo. Neither patients nor their clinicians were aware of which regimen they had been assigned.
At one year, patients taking tirzepatide had a 38% lower rate of cardiovascular death or worsening heart failure compared with the placebo group.
The researchers used two strategies for assessing kidney function, measuring creatinine and cystatin C at 12, 24 and 52 weeks. Ultimately, participants taking tirzepatide showed significant improvements over those taking placebo in terms of both markers of kidney function, although the results showed different patterns over time and among different patient groups.
Reference: Packer, M, Zile, M, Kramer, C. et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. JACC. null2025, 0 (0). https://doi.org/10.1016/j.jacc.2025.03.009
Full View
Tags:    
Article Source : JACC

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Bhumika Maikhuri

Dr Bhumika Maikhuri is an orthodontist with 2 years of clinical experience. She is also working as a medical writer and anchor at Medical Dialogues. She has completed her BDS from Dr D.Y. Patil Medical College and Hospital and MDS from Kalinga Institute of Dental Sciences. She has a few publications and patents to her credit. Her diverse background in clinical dentistry and academic research uniquely positions her to contribute meaningfully to our team.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Indian Study Shows Type 2 Diabetes Remission May Be Possible without Surgery or Extreme Diets

Shedding Weight, Losing Muscle: Study Links GLP-1 Drugs to Reduced Muscle Mass

Non-Invasive Saliva Test May Detect Early Signs of Diabetes and Obesity: Study Finds

Low Blood Sugar Before Pregnancy May Raise Risk of Preterm Birth, Low Birth Weight: Study Finds

Even Few Workouts a Week Could Lower Death Risk for People with Diabetes: Study Suggests

Yoga May Reduce the Risk of Developing Diabetes by 40 Percent: Study Shows

Medical Bulletin 23/July/2025

These Chemicals May Raise Type 2 Diabetes Risk by 31 Percent: Study Finds